Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02244801 · ClinicalTrials.gov registry record · Phase 1
Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation (The ONE Study )
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02244801 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 6 participants.
The verdict
NCT02244801, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This Phase I pilot study will evaluate the safety, and tolerability of darTreg infusion for adult, de novo, living donor renal transplant recipients.
Interventions
- DRUG darTreg infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-04 |
| Est. Completion | 2018-08-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02244801
The ClinicalTrials.gov registry entry for NCT02244801 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which darTreg infusion is the first listed.
NCT02244801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02244801 about?
NCT02244801 is a clinical study titled "Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation (The ONE Study )". This Phase I pilot study will evaluate the safety, and tolerability of darTreg infusion for adult, de novo, living donor renal transplant recipients.
What is the current status of trial NCT02244801?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2015-04. Estimated completion is 2018-08-28.
What interventions are being tested in trial NCT02244801?
The interventions under investigation include: darTreg infusion (DRUG).
Who is sponsoring clinical trial NCT02244801?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.